CSRT.L
Latest Trade
712.00GBpChange
-16.00(-2.20%)Volume
46,287Today's Range
-
740.0052 Week Range
-
1,110.00As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
Previous Close | 728.00 |
|---|---|
Open | 740.00 |
Volume | 46,287 |
3M AVG Volume | 1.32 |
Today's High | 740.00 |
Today's Low | 712.00 |
52 Week High | 1,110.00 |
52 Week Low | 700.00 |
Shares Out (MIL) | 49.36 |
Market Cap (MIL) | 359.37 |
Forward P/E | 13.93 |
Dividend (Yield %) | -- |
Consort Medical Says Now Expects Cramlington Incident To Hit Oper. Profit By 7-9 Mln Stg
Consort Medical Says Incident At Cramlington Facility To Hit FY Profit By 3-5 Mln Stg
Consort Medical Says FY Net Debt At £97.4 Mln
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company's principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica. Bespak's core business is the manufacture of inhaled drug delivery devices for life sciences partners and its operations are based in the United Kingdom. The Aesica business manufactures and sells active pharmaceutical ingredients (API), formulated pharmaceutical products and packaging services to the pharmaceutical industry and its operations are based in the United Kingdom and Europe. It offers its services to customers, such as pharmaceutical companies and life sciences. Its device products include metered dose inhalers, dry powder devices, actuators, dose counters, disposable auto-injectors, nasal devices and point-of-care diagnostics devices.
Industry
Medical Equipment & Supplies
Executive Leadership
Christopher Brinsmead
Non-Executive independent Chairman of the Board
Jonathan M. Glenn
Chief Executive, Executive Director
Paul Andrew Hayes
Chief Financial Officer, Executive Director
Manja Boerman
President - Aesica
Keyvan Djamarani
President - Bespak
Price To Earnings (TTM) | 34.25 |
|---|---|
Price To Sales (TTM) | 1.18 |
Price To Book (MRQ) | 1.51 |
Price To Cash Flow (TTM) | 10.24 |
Total Debt To Equity (MRQ) | 46.56 |
LT Debt To Equity (MRQ) | 46.56 |
Return on Investment (TTM) | 3.15 |
Return on Equity (TTM) | 2.24 |
Britain's Consort Medical Plc said on Monday it had agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.
Consort Medical Plc has agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc .
* Paul Hayes, group finance director, has informed board that he will be leaving Vitec to become chief financial officer of Consort Medical Plc
* Paul Hayes, finance director of Vitec Group Plc, is to succeed Richard Cotton as Consort Medical's group chief financial officer Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.